Interleukin-2

Links to news articles on Interleukin-2 .

Oxford BioMedica: TroVax clinical trial results to be reported at ... -- 30 Mar 2006
...initiated trial is sponsored by Cancer Research UK. "A Phase I clinical trial of MVA vaccine expressing 5T4 and high-dose interleukin-2 for metastatic renal ... PharmaLive.com (press release),

Swiss OK for Bayer/Onyx' Nexavar -- 30 Mar 2006
...three to six months on average, but it also appears to be much less toxic than current treatments for this type of cancer, such as interleukin-2 or interferon ... Pharma Times (subscription),

MS drug works in surprise way -- 30 Mar 2006
T-cells need a growth factor called interleukin 2 to function, so drugs that prevent T-cells from feeding on the growth factor could control multiple sclerosis ... Cincinnati Enquirer,

International Award Honors Discoveries In Cellular And Molecular ... -- Mar 23, 2006
Interferons interfere with the division of cancer cells and can slow tumor growth; interleukin-2, discovered by Robert Gallo and colleagues, stimulates the ... Medical News Today (press release),

Thalomid® and IL-2 Effective for Metastatic Renal Cell Carcinoma -- Mar 20, 2006
2 (IL-2) and Thalomid (thalidomide) results in a 52% disease control rate. The details of this study appeared in the April 1, 2006, issue of Cancer . ... Cancer Consultants (press release),

Role Of Thalidomide And Subcutaneous Interleukin 2 In Metastatic ... -- Mar 8, 2006
...not forget that these agents are not the panacea for kidney cancer. ... immunomodulatory agent thalidomide, in combination with subcutaneous interleukin 2 (SCIL-2 ... UroToday,

EpiCept Reports 2005 Operating and Financial Results -- Mar 15, 2006
...controlled Phase III trial investigating Ceplene plus IL-2 (interleukin-2) in the ... into Phase I clinical studies in solid tumors and metastatic brain cancer. ... MSN Money

New treatments based on T-cell stimulation possible -- Mar 3, 2006
...that was injected was specific to interleukin-2 (IL-2), a naturally occurring protein and a known immunotherapy for metastatic melanoma and renal cancer. ... In-PharmaTechnologist.com,

Biomira Inc. announces year-end results -- Mar 9, 2006
...program, Merck has shown its strong and continued commitment to cancer vaccines and to ... This company was created to fully exploit Liposomal Interleukin-2 (L-IL-2 ... Yahoo! News (press release)

EpiCept Reports 2005 Operating and Financial Results -- Mar 15, 2006
Cancer: Ceplene Ceplene is EpiCept's registration-stage compound for the treatment of ... Phase III trial investigating Ceplene plus IL-2 (interleukin-2) in the ... PR Newswire (press release),

Researchers Discover Molecule Allowing Cancer to Spread -- Mar 8, 2006
...candidates for immunotherapeutic treatment using agents such as Interleukin-2 (IL-2 ... 35,000 patients each year are diagnosed with kidney cancer and approximately ... eMaxHealth.com,

Do 73% of Americans Die from Just One Actual Disease -- Mar 6, 2006
...enhance mood and sleep, reduce nervousness and chronic fatigue, fight cancer and heart ... including TNF-a tumor necrosis factor alpha, IL-2 interleukin 2, IL-6 ... ClickPress (press release),

Mesothelioma Treatment 101 -- Mar 2, 2006
...it may benefit patients with bladder cancer). Mesothelioma cells proved susceptible to in vitro lysis by LAK cells following activation by interleukin-2 (IL-2 ... Only Idol,

Drugs trial system 'must be reviewed' -- Mar 19, 2006
...system. They include a chemical called interleukin-2, which helps white blood cells to recognise and destroy certain cancer cells. ... Manchester Evening News,

Patients vs. Paternalism -- Mar 6, 2006
A more recent example is aldesleukin (also known as interleukin-2, or IL-2), a drug that has offered new hope to victims of kidney cancer and malignant melanoma ... TCS Daily,

Clinical Data Evaluating CC-10004 As New Oral Therapy in Severe ... -- Mar 6, 2006
...of multiple proinflammatory mediators including PDE-4, TNF-alpha, interleukin-2 (IL-2 ... of innovative therapies for the treatment of cancer and inflammatory ... International News Service,

New Treatment For Kidney And Skin Cancer -- Dec 27, 2005
...odds against kidney cancer. A new treatment called Interleukin-2 looks promising for people who have kidney cancer or melanoma. ... KLTV,

FDA Approvals: Nexavar and Tamiflu -- Dec 28, 2005
...who had not received conventional treatment with biologics such as interleukin-2 or interferon ... additional phase 3 trial in non-small cell lung cancer is planned ... Medscape (subscription)

EpiCept Corporation and Maxim Pharmaceuticals Announce Trading and ... -- Dec 28, 2005
...dedicated to developing innovative cancer therapeutics. Maxim has completed one Phase 3 clinical trial of Ceplene(TM) plus Interleukin-2 combination therapy as ... Business Wire (press release),

EpiCept Corporation and Maxim Pharmaceuticals Announce Trading and ... -- Dec 28, 2005
...dedicated to developinginnovative cancer therapeutics. Maxim has completed one Phase 3clinical trial of Ceplene(TM) plus Interleukin-2 combination therapyas a ... Finanzen.net,

New Treatment For Advanced Kidney Cancer -- Dec 22, 2005
Two studies in patients with advanced kidney cancer have shown that ... study, most patients had previously received treatment with interleukin-2 or interferon. ... Hardbeatnews.com,

Zenotech to launch two bio generics in Feb, plans GDR -- Dec 20, 2005
...to launch in February next two generic biological products, used in cancer therapy. ... is planning to launch another bio generic for oncology, Interleukin-2 (IL-2 ... Newindpress,

FDA Approves Drug for Advanced Kidney Cancer -- Dec 20, 2005
...study recruited patients who had previously been treated with interleukin-2 or inteferon ... Kidney cancer accounts for approximately 3% of all adult cancers in the ... MedPage Today,

New-generation drug OK'd to treat advanced kidney cancer -- Dec 20, 2005
The current standard treatment for kidney cancer - immune therapy with interferon or interleukin-2 - has only modest benefits and can be extremely toxic. ... Monterey County Herald,

New Data Suggest Novel Low-dose Outpatient Chemobiotherapy Regimen ... -- Dec 12, 2005
...m(2) to a maximum 250 mcg, Interferon-alpha-2b at 5 MU and interleukin-2 at 4 MU ... More than one million new cases of skin cancer will be diagnosed in the United ... PR Newswire (press release),

Active Biotech Reports Interim Results of ANYARA Phase I Clinical ... -- Dec 14, 2005
...number of patients, says Dr. Roger Cohen at the Fox Chase Cancer Center in ... These include a sustained level of the immunostimulatory cytokine Interleukin 2 (IL-2 ... Market Wire (press release)

Transgene: Clinical Pipeline Update -- Nov 29, 2005
About TG4010 and lung cancer: TG4010 uses the Modified Vaccinia Ankara virus ... epitopes of MUC1; - The sequence coding for the cytokine Interleukin 2 (IL2) is ... PR Newswire (press release),

(Euronext Paris) - Transgene : Clinical Pipeline Update -- Nov 29, 2005
...and radiotherapy treatment of stages IIIB and IV lung cancer, survival rates ... The sequence coding for the cytokine interleukin 2 (IL-2) is included to help ... Euronext,

UW Medical Center opens Melanoma Center to provide advanced ... -- Nov 30, 2005
...be followed by chemotherapy, radiation therapy or biological therapy (using the body's immune system to fight the cancer, with interferon or interleukin-2). ... uwnews.org,

The lowdown on thyroid slowdown -- Dec 11, 2005
...lithium; interferon alpha, which is used to treat hepatitis C and certain types of leukemia and other cancers; and the cancer drug interleukin-2. Drugs taken ... ITP.net,

Fatigue And Hypothyroidism -- Dec 6, 2005
...medication lithium; interferon alpha, which is used to treat hepatitis C and certain types of leukemia and other cancers; and the cancer drug interleukin-2. ... Hollister Free Lance,

Sunitinib Promising for Metastatic Renal Cell Carcinoma -- Nov 18, 2005
...radiation therapy, and immune stimulating agents such as Proleukin® (interleukin-2). In an ... therapies that target a specific component of a cancer cell) are ... Cancer Consultants (press release),

2nd Phase II Trial with Trovax® in Renal Cell Carcinoma, Oxford ... -- Nov 19, 2005
2 (IL-2) in patients with metastatic renal cell carcinoma (RCC). There are now five Phase II trials ongoing with TroVax in RCC and colorectal cancer. ... Medical News Today (press release),

Mayo Clinic Researchers Discover Molecule Allowing Cancer to ... -- Nov 15, 2005
...candidates for immunotherapeutic treatment using agents such as Interleukin-2 (IL-2 ... 35,000 patients each year are diagnosed with kidney cancer and approximately ... AScribe

Cadila to market anti-cancer drug -- Nov 14, 2005
The two other anti cancer drugs Interferon Gama and Interleukin 2 on the other hand will be marketed only by 2007, he said. | Read more Finance news. |. ... Sify,

FDA Orphan Drug Approvals: Zactima, Surfaxin, IL-21 -- Nov 8, 2005
Agency for orphan drug status in the treatment of medullary thyroid cancer. On Oct. ... activity and found to be structurally similar to interleukin 2, an approved ... Medscape (subscription)

Fundamental Flaws of Hormesis for Public Health Decisions -- Oct 22, 2005
...cell replication, DNA synthesis; blood pressure, heart rate, interleukin-2 release, prolactin ... between domestic radon exposure and lung cancer mortality (Cohen ... Food Consumer,

Clinical Briefs For November 2005 -- Oct 30, 2005
Interleukin-2 (IL-2), an immune-boosting drug used experimentally in HIV therapy ... Researchers at the University of Minnesota Cancer Center and the National ... U.S. Medicine,

Modifying Immune System Response to Cancer Chemotherapy Could Lead ... -- Nov 2, 2005
Depletion of "suppressor" T-cells increases immune response in cancer patients ... by which this occurs is not entirely clear, but could involve interleukin-2 (IL-2 ... Kansas City infoZine,

Special Meeting of Maxim Stockholders to Be Held on December 21 ... -- Nov 14, 2005
...dedicated to developing innovative cancer therapeutics. Maxim has completed one Phase 3 clinical trial of Ceplene(TM) plus Interleukin-2 combination therapy as ... Genetic Engineering News,

New ECCO studies highlight promising potential of cancer ... -- Nov 2, 2005
A significant increase when compared to the standard therapy of renal cancer (high dose interleukin-2) which produced a median progression-free survival of 3.1 ... EurekAlert (press release),

Biomira to present at Bio-Europe 2005 -- Nov 7, 2005
...sought by Biomira as well as out-licensing opportunities: - Liposomal Interleukin-2 (L-IL ... based liposomal vaccine program in non-small cell lung cancer (NSCLC). ... PR Newswire (press release),

Special Meeting of Maxim Stockholders to Be Held on December 21 ... -- Nov 14, 2005
...dedicated to developinginnovative cancer therapeutics. Maxim has completed one Phase 3clinical trial of Ceplene(TM) plus Interleukin-2 combination therapyas a ... Finanzen.net,

Biomira to present at Bio-Europe 2005 -- Nov 7, 2005
Liposomal Interleukin-2 (L-IL ... product candidate, BLP25 Liposome Vaccine (L-BLP25), a MUC1-based liposomal vaccine program in non-small cell lung cancer (NSCLC ... Yahoo! News (press release)

Mesothelioma Treatment 101 -- Oct 25, 2005
...it may benefit patients with bladder cancer). Mesothelioma cells proved susceptible to in vitro lysis by LAK cells following activation by interleukin-2 (IL-2 ... juiceenewsdaily,

From the analyst's couch: TLR-targeted therapeutics -- Oct 31, 2005
...appropriate immune response to infection, initiate recognition of cancer antigens or ... less subtle immune system stimulators, such as interleukin-2 or interferons ... Nature.com (subscription),

... Go to the Article -- Nov 1, 2005
...a genetically engineered version of interleukin-2 (IL-2), a natural protein that stimulates the immune system to attack certain kinds of cancer cells. ... CancerWise

Roche and Protein Design Labs to Jointly Develop Daclizumab in ... -- Nov 1, 2005
...leaders in diagnostics, the leading supplier of pharmaceuticals for cancer, as well ... Zenapax is a humanized monoclonal antibody that blocks interleukin-2 (IL- 2 ... PharmaLive.com (press release),

More information on Interleukin-2 from the National Cancer Institute

Biological therapy is a type of treatment that works with your immune system. It can help fight cancer or help control side effects (how your body reacts to the drugs you are taking) from other cancer treatments like chemotherapy.

What is the difference between biological therapy and chemotherapy?

Biological therapy and chemotherapy are both treatments that fight cancer. While they may seem alike, they work in different ways. Biological therapy helps your immune system fight cancer. Chemotherapy attacks the cancer cells directly.

How does biological therapy fight cancer?

Doctors are not sure how biological therapy helps your immune system fight cancer. But they think it may:

Stop or slow the growth of cancer cells.
Make it easier for your immune system to destroy, or get rid of, cancer cells.
Keep cancer from spreading to other parts of your body.